167 related articles for article (PubMed ID: 17952842)
1. Adiponectin concentrations increase during acute FFA elevation in humans treated with rosiglitazone.
Krzyzanowska K; Mittermayer F; Krugluger W; Roden M; Schernthaner G; Wolzt M
Horm Metab Res; 2007 Oct; 39(10):769-72. PubMed ID: 17952842
[TBL] [Abstract][Full Text] [Related]
2. Free fatty acids normalize a rosiglitazone-induced visfatin release.
Haider DG; Mittermayer F; Schaller G; Artwohl M; Baumgartner-Parzer SM; Prager G; Roden M; Wolzt M
Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E885-90. PubMed ID: 16735449
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction.
Mittermayer F; Schaller G; Pleiner J; Krzyzanowska K; Kapiotis S; Roden M; Wolzt M
J Clin Endocrinol Metab; 2007 Jul; 92(7):2574-80. PubMed ID: 17473072
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
[TBL] [Abstract][Full Text] [Related]
6. Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.
Haider DG; Schindler K; Mittermayer F; Müller M; Nowotny P; Rieger A; Luger A; Ludvik B; Wolzt M
Clin Pharmacol Ther; 2007 Apr; 81(4):580-5. PubMed ID: 17235334
[TBL] [Abstract][Full Text] [Related]
7. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
[TBL] [Abstract][Full Text] [Related]
8. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
Barac A; Campia U; Matuskey LA; Lu L; Panza JA
Am J Cardiol; 2008 Apr; 101(7):980-5. PubMed ID: 18359318
[TBL] [Abstract][Full Text] [Related]
9. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
[TBL] [Abstract][Full Text] [Related]
10. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics.
Ghanim H; Dhindsa S; Aljada A; Chaudhuri A; Viswanathan P; Dandona P
J Clin Endocrinol Metab; 2006 Sep; 91(9):3553-8. PubMed ID: 16804037
[TBL] [Abstract][Full Text] [Related]
11. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.
Boden G; Homko C; Mozzoli M; Zhang M; Kresge K; Cheung P
Diabetes; 2007 Jan; 56(1):248-55. PubMed ID: 17192489
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
13. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
[TBL] [Abstract][Full Text] [Related]
14. Alcohol intake modifies leptin, adiponectin and resistin serum levels and their mRNA expressions in adipose tissue of rats.
Pravdova E; Macho L; Fickova M
Endocr Regul; 2009 Jul; 43(3):117-25. PubMed ID: 19817506
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy.
Sutinen J; Kannisto K; Korsheninnikova E; Fisher RM; Ehrenborg E; Nyman T; Virkamäki A; Funahashi T; Matsuzawa Y; Vidal H; Hamsten A; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E941-9. PubMed ID: 14749206
[TBL] [Abstract][Full Text] [Related]
16. Two-year effect of rosiglitazone in chinese poorly controlled type 2 diabetic patients.
Lee JK; Chu CH; Chuang MJ; Lin SC; Wang MC; Lu CC; Sun CC; Lam HC
Chang Gung Med J; 2006; 29(5):486-92. PubMed ID: 17214393
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
Krag MB; Nielsen S; Guo Z; Pedersen SB; Schmitz O; Christiansen JS; Jørgensen JO
Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
[TBL] [Abstract][Full Text] [Related]
18. The effects of recombinant human growth hormone (rhGH) supplementation on adipokines and C-reactive protein in obese subjects.
Albert SG; Haas MJ; Mooradian AD
Growth Horm IGF Res; 2007 Feb; 17(1):19-25. PubMed ID: 17118687
[TBL] [Abstract][Full Text] [Related]
19. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
20. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men.
Gouni-Berthold I; Berthold HK; Chamberland JP; Krone W; Mantzoros CS
Clin Endocrinol (Oxf); 2008 Apr; 68(4):536-41. PubMed ID: 17973945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
